Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.

Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA 3rd.

Clin Cancer Res. 2011 May 1;17(9):2997-3004. doi: 10.1158/1078-0432.CCR-10-3425. Epub 2011 Mar 17.

PMID:
21415214
[PubMed - indexed for MEDLINE]
Free Article
2.

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP.

Oncology. 2011;80(1-2):50-6. doi: 10.1159/000327739. Epub 2011 May 31.

PMID:
21625179
[PubMed - indexed for MEDLINE]
3.

Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.

Shimizu T, Okamoto I, Tamura K, Satoh T, Miyazaki M, Akashi Y, Ozaki T, Fukuoka M, Nakagawa K.

Cancer Chemother Pharmacol. 2010 Jan;65(2):243-50. doi: 10.1007/s00280-009-1028-3.

PMID:
19479254
[PubMed - indexed for MEDLINE]
4.

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Durden DL, Ramanathan RK.

Eur J Cancer. 2012 Dec;48(18):3319-27. doi: 10.1016/j.ejca.2012.06.027. Epub 2012 Aug 23.

PMID:
22921184
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.

Papadopoulos KP, Goel S, Beeram M, Wong A, Desai K, Haigentz M, Milián ML, Mani S, Tolcher A, Lalani AS, Sarantopoulos J.

Clin Cancer Res. 2008 Nov 1;14(21):7110-5. doi: 10.1158/1078-0432.CCR-08-0483.

PMID:
18981010
[PubMed - indexed for MEDLINE]
Free Article
6.

A first-in-human study of conatumumab in adult patients with advanced solid tumors.

Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM.

Clin Cancer Res. 2010 Dec 1;16(23):5883-91. doi: 10.1158/1078-0432.CCR-10-0631. Epub 2010 Oct 14.

PMID:
20947515
[PubMed - indexed for MEDLINE]
Free Article
7.

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR.

Cancer Chemother Pharmacol. 2010 Mar;65(4):791-801. doi: 10.1007/s00280-009-1188-1. Epub 2009 Dec 10.

PMID:
20012293
[PubMed - indexed for MEDLINE]
8.

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.

Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M.

J Clin Oncol. 1996 Jul;14(7):2020-30.

PMID:
8683232
[PubMed - indexed for MEDLINE]
9.

Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.

Jung D, Lin L, Jiao H, Cai X, Duan JX, Matteucci M.

Cancer Chemother Pharmacol. 2012 Mar;69(3):643-54. doi: 10.1007/s00280-011-1741-6. Epub 2011 Oct 1.

PMID:
21964906
[PubMed - indexed for MEDLINE]
10.

Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.

Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebch G, Siamopoulos K, Tzamakou E, Rammou D, Wolf L, Walker R, Hanauske A.

J Clin Oncol. 2000 Oct 15;18(20):3535-44.

PMID:
11032596
[PubMed - indexed for MEDLINE]
11.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2142-8. Review.

PMID:
12114414
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.

Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M.

Cancer Chemother Pharmacol. 2007 Jul;60(2):285-93. Epub 2006 Nov 30.

PMID:
17136542
[PubMed - indexed for MEDLINE]
13.

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.

Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L.

Clin Cancer Res. 2010 Jan 15;16(2):699-710. doi: 10.1158/1078-0432.CCR-09-1365. Epub 2010 Jan 12.

PMID:
20068101
[PubMed - indexed for MEDLINE]
Free Article
14.

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors.

Traynor AM, Gordon MS, Alberti D, Mendelson DS, Munsey MS, Wilding G, Gammans RE, Read WL.

Invest New Drugs. 2010 Aug;28(4):509-15. doi: 10.1007/s10637-009-9264-2. Epub 2009 May 13.

PMID:
19434370
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Hilgers W, Faivre S, Chieze S, Alexandre J, Lokiec F, Goldwasser F, Raymond E, Kahatt C, Taamma A, Weems G, MacDonald JR, Misset JL, Cvitkovic E.

Invest New Drugs. 2006 Jul;24(4):311-9.

PMID:
16683074
[PubMed - indexed for MEDLINE]
16.

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.

Traynor AM, Thomas JP, Ramanathan RK, Mody TD, Alberti D, Wilding G, Bailey HH.

Invest New Drugs. 2011 Apr;29(2):316-22. doi: 10.1007/s10637-009-9364-z. Epub 2009 Dec 9.

PMID:
19997959
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL.

J Clin Oncol. 2002 Sep 15;20(18):3841-9.

PMID:
12228203
[PubMed - indexed for MEDLINE]
18.

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK.

J Clin Oncol. 2001 Jul 1;19(13):3267-79.

PMID:
11432895
[PubMed - indexed for MEDLINE]
19.

Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule.

Awada A, Punt CJ, Piccart MJ, Van Tellingen O, Van Manen L, Kerger J, Groot Y, Wanders J, Verweij J, Wagener DJ.

Br J Cancer. 1999 Mar;79(9-10):1454-61.

PMID:
10188890
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk